Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Genentech
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 6 ans
Étude GO29674 : étude de phase 1, en escalade de dose, évaluant la tolérance de de l'association MOXR0916, un anticorps anti-OX40 avec l’Atezolizumab (MPDL3280a), un anticorps anti-PD-L1, chez des patients ayant une tumeur solide localement avancées ou métastatiques. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
GO29674 : Etude d'escalade de dose de phase Ib, en ouvert, visant à évaluer la sécurité et la pharmacocinétique de l'association MOXR0916 avec le MPDL3280a chez les patients présentant des tumeurs sol...
Country
France
organs
Tumeurs solides
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIb TRIAL COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED, RECURRENT, OR METASTATIC NON–SMALL CELL LUNG CANCER
The primary objective of this Phase IIIb study is to compare PFS in subjects randomized to bevacizumab + erlotinib versus bevacizumab + erlotinib-placebo in subjects with NSCLC who have completed four...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A MULTICENTER, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY UNTREATED METASTATIC BREAST CANCER
The primary objective of the study is to determine the clinical benefit of the addition of bevacizumab to standard chemotherapy regimens for previously untreated metastatic breast cancer, as measured ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Genentech Inc
Update Il y a 4 ans
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients
To evaluate the efficacy (as measured by progression-free survival [PFS]) of paclitaxel + GDC-0941 versus paclitaxel + placebo in patients with and without PIK3CA mutations and in all treated patients
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A clinical study to investigate the safety and efficacy of the product rhuMAb BETA7 in treating patients with ulcerative colitis, a form of inflammatory bowel disease Ensayo clínico para investigar la seguridad y eficacia del producto rhuMab Beta7 en tratamiento de pacientes con colitis ulcerosa, una enfermedad inflamatoria del intestino grueso
The primary objective of this study is to evaluate the efficacy of different doses of rhuMAb Beta7 compared with placebo in patients with moderate to severe UC. El objetivo principal de este est...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Genentech Inc
Update Il y a 4 ans
A Study of GDC-0810 versus Fulvestrant in Postmenopausal Women with Advanced or Metastatic ER+/HER2- Breast Cancer Resistant To Aromatase Inhibitor Therapy
• To evaluate the efficacy of GDC-0810 compared with fulvestrant in the intent to treat (ITT) population as measured by progression free survival (PFS) • To evaluate the efficacy of GDC-0810 compared ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
Genentech APO3585g : Essai de phase 1-2 randomisé évaluant l’efficacité et la tolérance d’un traitement associant Apo2L/TRAIL au rituximab chez des patients ayant un lymphome non hodgkinien. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase Ib/II, open-label, multicenter study of the safety, pharmacokinetics, and efficacy of APO2L/TRAIL administered intravenously in combination with rituximab to subjects with follicular and other...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
Étude GO29227 : étude de phase 2, randomisée, contrôlée contre placebo, comparant l’efficacité d’un traitement associant ipatasertib (GDC-0068), un inhibiteur de l’AKT, et paclitaxel par rapport à un traitement associant paclitaxel et placebo, en traitement de première ligne, chez des patientes ayant un cancer du sein triple négatif métastatique. [essai clos aux inclusions]
L’objectif de cette étude est de comparer l’efficacité d’un traitement associant ipatasertib (GDC-0068), un inhibiteur de l’AKT, et paclitaxel, par rapport à un traitement associant paclitaxel et plac...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF LEBRIKIZUMAB (MILR1444A)IN ADULT PATIENTS WITH ASTHMA WHO ARE INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROIDS
The main objectives for this study are as follows: - To assess the efficacy of lebrikizumab in improving asthma control in patients with asthma who remain inadequately controlled despite therapy wit...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For Treatment of Advanced Non−Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy
The primary objective of this Phase III study was to evaluate the efficacy of combining bevacizumab with Tarceva (erlotinib) relative to Tarceva monotherapy in patients receiving second-line therapy f...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
Next